TOP TEN perturbations for 39876_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39876_at
Selected probe(set): 201704_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39876_at (201704_at) across 6674 perturbations tested by GENEVESTIGATOR:

colorectal adenoma study 2 / normal colon tissue

Relative Expression (log2-ratio):-2.3064594
Number of Samples:5 / 6
Experimental colorectal adenoma study 2
Laser microdissected human adenoma sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

HIV-associated neurocognitive disorder study 7 (normal) / HIV-associated neurocognitive disorder study 6 (normal)

Relative Expression (log2-ratio):2.170642
Number of Samples:2 / 2
Experimental HIV-associated neurocognitive disorder study 7 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART).
Control HIV-associated neurocognitive disorder study 6 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients did not receive any antiretroviral therapy (ART).

prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):2.158163
Number of Samples:3 / 5
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-1.9482279
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):1.9042501
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

OPM-1 / MM1.S

Relative Expression (log2-ratio):-1.8752346
Number of Samples:4 / 4
Experimental OPM-1
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code:
Control MM1.S
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code:

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-1.801671
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-1.7463589
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-1.7131758
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):-1.7105112
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.